Login / Signup

Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.

Alireza GhajarFaezeh GholamianMaryam Tabatabei-MotlaghMohsen AfaridehFarzin RezaeiMaryam Ghazizadeh-HashemiShahin Akhondzadeh
Published in: Human psychopharmacology (2018)
Citicoline add-on therapy to risperidone can effectively improve the primary negative symptoms of patients with schizophrenia.
Keyphrases
  • double blind
  • bipolar disorder
  • open label
  • placebo controlled
  • randomized controlled trial
  • phase ii
  • depressive symptoms
  • cell therapy
  • smoking cessation